Abstract
The luteal phase is a critical component in supporting early pregnancy by forming the corpus luteum, and priming the endometrium for implantation following conception. Unfortunately, in assisted reproductive technology, ovarian stimulation protocols disrupt the hormonal milieu of the menstrual cycle, resulting in a largely defective luteal phase. For the last three decades, the optimum regimen for luteal phase support in assisted reproductive technology has been explored. Human chorionic gonadotropin was one of the first agents utilized to rescue the corpus luteum, given its high affinity for luteinizing hormone receptor. In this article, the author will summarize the role of human chorionic gonadotropin for luteal support in improving reproductive outcomes.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.